Un nouveau groupe sur Linkedin, en anglais, pour la e-pharma et les e-évangélistes. Pour la petite histoire, je crée le groupe dès que la fonction a été ouverte sur LINKEDIN , puis j’oublie et…. trois demandes de membres, tous américains !

Du coup j’ai décidé d’animer sérieusement le groupe, mais je voudrais :

• reprendre le flux sur ce blog (je vais le faire dans un widget je pense)
• faire un "bouton" join the group
• organiser les passerelles wordpress-linkedin

Prochaine étape, relier le groupe à mon profil FaceBook.

Les conseils seront les bienvenus car je voudrais le faire de manière efficace !

Et du coup, le forum intégré au blog n’a plus de sens, pour l’instant…

iGuard is the fastest and easiest way to get personalized,
safety alerts and updates about your medicines

Un service 2.0 de l’ère post VIOXX quoi ! C’est “Ma Pharmacovigilance à moi” un service tout simple ma qui devrait faire FUREUR non ???

En plus la réponse est graduée… Malin ! Un cauchemard de blockbuster ?

Click here to learn more about how our risk ratings (shown below) are assigned.

	Low Suitable for widespread use.
	General Use under normal care of a doctor.
	Guarded Be on the lookout for safety events.
	Elevated Create a personal risk reduction plan.
	High Carefully consider risk versus benefit.

A rapprocher des infos ci dessous (mais sermo méritera un billet en tant que média social médical):

Tracking Adverse Event “Signals” With Databases & Social Media

This morning (July 3rd) an interesting story appeared in the Wall Street Journal (subscription required) focusing on how databases and powerful software are enabling researchers to identify “signals” regarding the side effects of prescription medications. According to the article, Ralph Edwards, director of the World Health Organization’s, drug monitoring center: “[H]as amassed about four million reports of medical problems experienced by people taking prescription drugs. His job is to sift through these so-called adverse events, looking for ‘signals’ of potential side effects.” The Journal goes on to note:

“Sophisticated software allows health authorities to troll through huge databases looking for possible drug dangers. The data mining can detect rare side effects that didn’t show up in clinical trials. But it can also raise false alarms and force regulators to divert time and money from more pressing dangers.” Public health officials and pharmaceutical executives are facing similar issues when it comes to social media. Blogs, bulletin boards and social networks are providing people looking for real-time information about the safety and efficacy of drugs with valuable and sometimes controversial insights. For example, last year doctors using the social network Sermo reported that patients taking Lipitor were experiencing vivid and repeated nightmares.

This finding was the subject of national news and illustrated the power of social networks to highlight information that may warrant further investigation. People from pharmaceutical companies are understandably nervous about how this technology (i.e., statistical or social media analysis software) may impact their financial and regulatory fortunes.

However, when used carefully and appropriately, these tools can help pharma executives achieve their goal of developing and marketing safer medicines.